Published in J Med Chem on June 03, 2016
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) (2017) 0.75
miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med (2017) 0.75
Cdk9 and Spt5 are specifically required for expression of Herpes simplex virus 1 replication-dependent late genes. J Biol Chem (2017) 0.75
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem (2001) 5.36
7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature (2001) 5.11
Identification of multiple cyclin subunits of human P-TEFb. Genes Dev (1998) 4.73
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. Science (2007) 4.18
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II. Proc Natl Acad Sci U S A (1985) 3.98
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res (2007) 3.92
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol (2011) 3.72
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 3.53
Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem (2011) 3.31
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene (2006) 3.10
The exploration of macrocycles for drug discovery--an underexploited structural class. Nat Rev Drug Discov (2008) 2.94
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem (2005) 2.88
Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem (1994) 2.82
Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem (1997) 2.65
TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Mol Cell (2009) 2.61
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev (2012) 2.44
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J (2008) 2.36
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood (1998) 2.31
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res (1996) 2.24
Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186. J Biol Chem (2005) 2.24
TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol (2009) 2.20
The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov (2015) 2.15
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther (2010) 1.93
Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. Bioorg Med Chem (2006) 1.81
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol (2012) 1.74
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood (2013) 1.72
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences. J Biol Chem (2001) 1.63
Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem (2000) 1.59
RNAP II CTD phosphorylated on threonine-4 is required for histone mRNA 3' end processing. Science (2011) 1.54
Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nat Commun (2012) 1.49
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology (2007) 1.48
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res (2004) 1.47
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A (1996) 1.47
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci (2008) 1.46
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst (1992) 1.41
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res (1999) 1.40
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene (2008) 1.39
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res (2001) 1.37
Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep (2010) 1.36
7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. Wiley Interdiscip Rev RNA (2011) 1.34
Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene (2002) 1.33
Simple indole alkaloids and those with a nonrearranged monoterpenoid unit. Nat Prod Rep (2002) 1.26
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol (1999) 1.26
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs (2014) 1.26
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol (2002) 1.24
FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci (2015) 1.23
Phosphatase PPM1A regulates phosphorylation of Thr-186 in the Cdk9 T-loop. J Biol Chem (2008) 1.23
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res (2007) 1.23
Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity. Mol Cell Biol (1998) 1.22
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther (2007) 1.18
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer (2010) 1.16
Cyclin T: three forms for different roles in physiological and pathological functions. J Cell Physiol (2003) 1.15
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res (1997) 1.15
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res (2015) 1.13
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol (1993) 1.11
The structure and substrate specificity of human Cdk12/Cyclin K. Nat Commun (2014) 1.10
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther (2009) 1.09
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther (2009) 1.09
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol (2009) 1.08
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev (2014) 1.07
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev (2009) 1.06
Selective control of gene expression by CDK9 in human cells. J Cell Physiol (2010) 1.06
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res (2012) 1.05
Differential localization and expression of the Cdk9 42k and 55k isoforms. J Cell Physiol (2005) 1.05
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ (2013) 1.04
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. ACS Med Chem Lett (2010) 1.04
Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. Gene (2005) 1.03
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem (2004) 1.02
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem (2006) 1.02
Cyclin-dependent kinase inhibitors move into Phase III. Nat Rev Drug Discov (2012) 1.02
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia (2011) 1.02
Total syntheses of variolin B and deoxyvariolin B. J Org Chem (2003) 1.00
Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res (2011) 0.99
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia (2009) 0.99
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol (2004) 0.99
Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene (2000) 0.98
P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther (2007) 0.98
Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation. J Biol Chem (2012) 0.97
Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res (2007) 0.97
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs (2013) 0.96
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 0.96
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors. Bioorg Med Chem Lett (2007) 0.96
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Mol Cancer Ther (2015) 0.95
Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem (2009) 0.95
AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res (2006) 0.95
Indole alkaloids from the tunicate Aplidium meridianum. J Nat Prod (1998) 0.95
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood (2013) 0.94
Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem (2008) 0.94
CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells. J Virol (2013) 0.93
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia (2013) 0.92